R. Zeiser Et Al. , "Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.," The New England journal of medicine , vol.385, pp.228-238, 2021
Zeiser, R. Et Al. 2021. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.. The New England journal of medicine , vol.385 , 228-238.
Zeiser, R., Polverelli, N., Ram, R., Hashmi, S. K., Chakraverty, R., Middeke, J. M., ... Musso, M.(2021). Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.. The New England journal of medicine , vol.385, 228-238.
Zeiser, Robert Et Al. "Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.," The New England journal of medicine , vol.385, 228-238, 2021
Zeiser, Robert Et Al. "Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.." The New England journal of medicine , vol.385, pp.228-238, 2021
Zeiser, R. Et Al. (2021) . "Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.." The New England journal of medicine , vol.385, pp.228-238.
@article{article, author={Robert Zeiser Et Al. }, title={Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.}, journal={The New England journal of medicine}, year=2021, pages={228-238} }